Grupo Menarini Competitors and Similar CompaniesClear all

Grupo Menarini's competitors and similar companies include Quantum Pharmaceutical, AOP Orphan Pharmaceuticals, Yuyu Pharma and MEDINFAR.

	Grupo Menarini Grupo Menarini is a pharmaceutical company.	Quantum Pharmaceutical Quantum Pharmaceutical is a manufacturer and supplier of unlicensed medicines and hard-to-source products.	AOP Orphan Pharmaceuticals AOP Orphan is a company focused on clinical development, marketing and distribution of medicines for rare and complex diseases.	Yuyu Pharma Yuyu Pharma (유유제약, formerly known as YuYu) is a company that manufactures, distributes, and develops medicines.	MEDINFAR MEDINFAR manufacture of pharmaceutical products.
Founding Date	Founding Date 1961	Founding Date 2004	Founding Date 1996	Founding Date 1941	Founding Date 1970
Type	Type Private	Type Subsidiary	Type Private	Type Public	Type Private
Tags	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma	Tags Healthcare distribution drug development pharma
Locations	Locations Badalona, ES HQ	Locations Hobson, GB HQ	Locations Wien, AT HQ Sofia, BG Meudon, FR Ismaning, DE Athina, GR Budapest, HU see more	Locations Seoul, KR HQ Anyang, KR Bucheon, KR Busan, KR Changwon Si, KR Daegu, KR Daejeon, KR see more	Locations Venda Nova, PT HQ Lisboa, PT
Employees	Employees 5541% increase	Employees 4548% increase	Employees 5352% increase	Employees 253	Employees 404
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) £76.1m (FY, 2018)	Revenue (est.) N/A	Revenue (est.) ₩137.2b (FY, 2023)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods £54.5m (FY, 2018)	Cost of goods N/A	Cost of goods ₩85.1b (FY, 2023)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit £21.6m (FY, 2018)	Gross profit N/A	Gross profit ₩53.4b (FY, 2023)	Gross profit N/A
Net income	Net income N/A	Net income (£8.3m) (FY, 2018)	Net income N/A	Net income (₩5.5b) (FY, 2023)	Net income N/A